NCT04905212 — "A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy" trial site landscape

Public-registry site landscape for NCT04905212, “A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy”, a IgA Nephropathy study sponsored by RemeGen Co., Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT04905212 (registry record)
Study title	A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy
Official title	A Phase 2, Randomized, Double-Blind, Multicenter Study of Telitacicept for Injection (RC18) With an Optional Open Label Extension in Subjects With IgA Nephropathy
Sponsor	RemeGen Co., Ltd.
Condition(s)	IgA Nephropathy
Phase	PHASE2
Listed sites	8
Intervention(s)	Telitacicept 160mg, Telitacicept 240mg, Placebo
Site countries	United States

Patient-friendly overview of this study: eichor.com/study/NCT04905212.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT04905212 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →